KLOW Peptide Dosage Calculator (80 mg Blend)
A vendor-defined four-peptide blend with no standard composition, no published research on the blend itself, and no dose anywhere in the literature.
Written by Kashif Khan, who builds and maintains this site and is not a clinician. Every figure links to its primary source.
Not approved; no FDA recognition of the blend
KLOW is a seller's product name, not a drug. There is no monograph, no United States Adopted Name and no identity standard for it. Three of its four components — BPC-157, thymosin beta-4 and KPV — appear in no category of the FDA's nominated bulk substances list. The fourth is more complicated than the marketing suggests: GHK-Cu was removed from Category 1 on 22 April 2026 when its nominations were withdrawn, then on 5 May 2026 a nominator clarified that it had meant to withdraw only the injectable route, so “GHK-Cu (except for injectable routes of administration)” is being added back. Injectable GHK-Cu — the form in this vial — is on no list, and the FDA has said it intends to consult its advisory committee before the end of February 2027 on whether GHK-Cu belongs on the 503A list at all.
No approved human dose exists for this compound in any country. The figures below are the doses used in named published studies, reproduced for reference only. Doses given to rats or mice do not convert to a human dose. The FDA has stated that labelling a product “research use only” or “not for human consumption” does not change its legal status when the seller's own marketing shows it is intended for people.
Anti-doping: Prohibited at all times. Contains BPC-157 (class S0) and thymosin beta-4 (class S2).
Key facts
- Half-life
- Not published. No accessible human pharmacokinetic study reports one, so any specific figure quoted elsewhere has no primary source behind it.
- Also sold as
- KLOW peptide
Published doses
How good is the evidence?
Zero published data on the blend itself: no pharmacokinetics, no safety, no efficacy, and no compatibility or stability study of the four peptides co-formulated in one vial. Not a single paper, abstract or registered trial names it — a literature search for the blend returns nothing at all. Only the four ingredients separately have been studied, and none of those four has a published human injectable dose.
Four components, one volume, and no way to separate them
The common commercial split is 50 mg of GHK-Cu to 10 mg each of BPC-157, TB-500 and KPV — but it is a ratio, not a standard, and different sellers use different ones. In an 80 mg vial reconstituted with 4 mL, that split gives 12.5 mg/mL of GHK-Cu and 2.5 mg/mL of each of the other three, so every millilitre drawn delivers five times as much GHK-Cu as anything else.
That proportion is fixed at the moment the vial is filled and there is no operation you can perform afterwards that changes it. Adding water dilutes all four equally. Drawing less takes less of all four. If any one of the four is the reason you bought the vial, the other three arrive with it in whatever amount the seller chose, and the only way to change that is a different vial.
With four components the ambiguity in the label compounds too. A total mass with no per-component split leaves four unknowns rather than two, and the calculator on this page cannot recover them — it can only work from what your own label states.
What a literature search for this blend returns
Nothing. Not a paper, not an abstract, not a registered trial naming the combination. There is no pharmacokinetic data for it, no safety data, no efficacy data, and — the omission that matters most for a vial holding four peptides in one solution — no compatibility or stability study of the four co-formulated together.
That last gap is specific to blends and is worth separating from the general absence of evidence. Whether four peptides remain stable in a shared solution, and whether any of them interacts with the others or with the copper in GHK-Cu, is a formulation question with a measurable answer that nobody has measured. An approved product would have to answer it before shipping. A vendor-defined blend does not.
What has been studied is the four ingredients separately, and none of the four has a published human injectable dose. So the blend is not four known quantities combined — it is four unknowns combined, in a ratio chosen by the seller, with the combination itself unstudied.
Common questions
Sources
Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.
- RegulatorFDA· 2026-05-14Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
- RegulatorFDACertain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
- RegulatorFDA· 2026-07July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
- RegulatorWorld Anti-Doping Agency· 2026WADA 2026 Prohibited List
- Published studyAmerican Journal of Sports Medicine 2026;54(1):223–9· 2026-01Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
- ReferenceClinicalTrials.gov· 2015-10NCT02637284 — PCO-02 (oral BPC-157) phase 1 safety and pharmacokinetics in healthy volunteers
- Published studyAnnals of the New York Academy of Sciences 2010;1194:223–9· 2010-04Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta 4 in healthy volunteers
- RegulatorFDACompounding Risk Alerts